Holen Sie sich die Stockscreener-App
41.27
3.54%
1.41
Handel nachbörslich:
41.49
0.22
+0.53%
Schlusskurs vom Vortag:
$39.86
Offen:
$40.53
24-Stunden-Volumen:
4.49M
Relative Volume:
1.23
Marktkapitalisierung:
$4.64B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-44.38
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
+29.45%
1M Leistung:
+32.66%
6M Leistung:
+39.90%
1J Leistung:
-26.57%
1-Tages-Spanne:
$39.88
$41.68
1-Wochen-Bereich:
$32.92
$41.68
52-Wochen-Spanne:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
41.27 | 4.48B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Why Is Viking Therapeutics Stock Gaining Wednesday?Viking Therapeutics (NASDAQ:VKTX) - Benzinga
The 3 Things That Matter for Viking Therapeutics Now - Yahoo Finance
IBD Rating Upgrades: Viking Therapeutics Shows Improved Price Strength - Investor's Business Daily
How does Viking Therapeutics Inc. correlate with NasdaqBreakout Return Surge Ideas - thegnnews.com
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - The Globe and Mail
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - The Motley Fool
Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735 - Insider Monkey
Viking Therapeutics Inc. Builds Base for Possible ReboundCommunity Entry Consensus Trade Ideas Shared - beatles.ru
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts - AOL.com
Viking Therapeutics Surges 6.55% on High-Volume Momentum Ranking 373rd as Liquidity-Driven Strategy Yields 166.71% Return - AInvest
Viking Therapeutics Stock Climbs on Promising Drug Results - TipRanks
Viking Therapeutics' VK2735 maintains competitive edge despite disappointing Eli Lilly data. - AInvest
Viking Therapeutics' VK2735 Shows Promising Phase 1 Results, Justifying Buy Rating - AInvest
Viking Therapeutics Surges 11.54% to 408th in Volume Amid Eli Lilly's Setback - AInvest
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Why Viking Therapeutics Stock is Climbing - TipRanks
Promising Phase 1 Results for Viking Therapeutics’ VK2735 Justify Buy Rating - TipRanks
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - Benzinga
Eli Lilly’s obesity drug data lifts Viking Therapeutics stock By Investing.com - Investing.com Canada
Viking Therapeutics Soars 11.39% on Acquisition Hopes, Obesity Drug Progress - AInvest
Three Stocks Showing Strong Buy Signals - AInvest
Unlocking Viking Therapeutics' Potential with Upcoming Clinical Data - AInvest
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial - MSN
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True? - MSN
This Biotech Stock Could Soar on Upcoming Clinical Data - AOL.com
Two Biotech Stocks with High Upside Potential: Viking Therapeutics and Recursion Pharmaceuticals - AInvest
What is the risk reward ratio of investing in Viking Therapeutics Inc. stockUnmatched market gains - Jammu Links News
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales - The Globe and Mail
What institutional investors are buying Viking Therapeutics Inc. stockNavigate the market with precision tools - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - Yahoo Finance
When is Viking Therapeutics Inc. stock expected to show significant growthIdentify safe investments with exceptional yields - Jammu Links News
What is the dividend policy of Viking Therapeutics Inc. stockExplosive earnings growth - Jammu Links News
What makes Viking Therapeutics Inc. stock price move sharplyGet professional advice for portfolio optimization - Jammu Links News
Is it the right time to buy Viking Therapeutics Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
Is Viking Therapeutics Inc. stock overvalued or undervaluedFree Stock Selection - Jammu Links News
What are analysts’ price targets for Viking Therapeutics Inc. in the next 12 monthsMarket-beating returns - Jammu Links News
Is Viking Therapeutics the Next Big Biotech Bet? - AOL.com
Viking Therapeutics: A Promising Buy with Strategic Opportunities in Obesity Treatment and Direct-to-Consumer Market - TipRanks
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - AOL.com
Viking Bets Big On Obesity And NASH With Dual-Agonist Pipeline - Finimize
Axsome Therapeutics and Viking Therapeutics: Biotech Stocks to WatchNews and Statistics - IndexBox
Wall Street Predicts Axsome Therapeutics and Viking Therapeutics Stocks to Soar 74% to 159% - AInvest
Why Viking Therapeutics Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
Sentiment Turns Positive on Viking Therapeutics Inc. — Reversal AheadMarket Entry and Exit Point Tips From Traders - metal.it
How does Viking Therapeutics Inc. compare to its industry peersDynamic investment growth - Jammu Links News
Raymond James Financial Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - MarketBeat
Why is Viking Therapeutics Inc. stock attracting strong analyst attentionTriple returns potential - Jammu Links News
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 03 '25 |
Sale |
27.76 |
4,266 |
118,428 |
168,660 |
| Mancini Marianna | Chief Operating Officer |
Jul 03 '25 |
Sale |
27.77 |
4,266 |
118,473 |
377,535 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):